Advanced search
Publication Cover
Expert Review of Anticancer Therapy Volume 13, 2013 - Issue 9
Submit an article Journal homepage
67
Views
0
CrossRef citations to date
0
Altmetric
Theme: Leukemia & Lymphoma - Review

The role of chemotherapy in managing chronic lymphocytic leukemia: optimizing combinations with targeted therapy

Loretta J Nastoupil Department of Hematology Oncology, Winship Cancer Institute, Emory University, Atlanta, GA 30322, USA
,
Rajni Sinha Department of Hematology Oncology, Winship Cancer Institute, Emory University, Atlanta, GA 30322, USA
&
Christopher R Flowers Department of Hematology Oncology, Winship Cancer Institute, Emory University, Atlanta, GA 30322, USA. [email protected]
Pages 1089-1108 | Published online: 10 Jan 2014

References

  • CLL Trialists’ Collaborative Group. Chemotherapeutic options in chronic lymphocytic leukemia: a meta-analysis of the randomized trials. J. Natl. Cancer Inst. 91(10), 861–868 (1999).
  • Rai KR, Sawitsky A, Cronkite EP, Chanana AD, Levy RN, Pasternack BS. Clinical staging of chronic lymphocytic leukemia. Blood 46(2), 219–234 (1975).
  • Binet JL, Auquier A, Dighiero G et al. A new prognostic classification of chronic lymphocytic leukemia derived from a multivariate survival analysis. Cancer 48(1), 198–206 (1981).
  • Hallek M, Cheson BD, Catovsky D et al.; International Workshop on Chronic Lymphocytic Leukemia. Guidelines for the diagnosis and treatment of chronic lymphocytic leukemia: a report from the International Workshop on Chronic Lymphocytic Leukemia updating the National Cancer Institute-Working Group 1996 guidelines. Blood 111(12), 5446–5456 (2008).
  • Eichhorst B, Goede V, Hallek M. Treatment of elderly patients with chronic lymphocytic leukemia. Leuk. Lymphoma 50(2), 171–178 (2009).
  • Cramer P, Hallek M. Prognostic factors in chronic lymphocytic leukemia – what do we need to know? Nat. Rev. Clin. Oncol. 8(1), 38–47 (2011).
  • Shanafelt TD. Predicting clinical outcome in CLL: how and why. Hematology Am. Soc. Hematol. Educ. Program 421–429 (2009).
  • Bergmann MA, Eichhorst BF, Busch R et al. Prospective evaluation of prognostic parameters in early stage chronic lymphocytic leukemia (CLL): results of the CLL1-protocol of the German CLL Study Group (GCLLSG). Presented at: American Society of Hematology 49th Annual Meeting. Atlanta, GA, USA, 8–11 December 2007. Blood 110(11), Abstract 625 (2007).
  • Montserrat E, Sanchez-Bisono J, Viñolas N, Rozman C. Lymphocyte doubling time in chronic lymphocytic leukaemia: analysis of its prognostic significance. Br. J. Haematol. 62(3), 567–575 (1986).
  • Hamblin TJ, Davis Z, Gardiner A, Oscier DG, Stevenson FK. Unmutated Ig V(H) genes are associated with a more aggressive form of chronic lymphocytic leukemia. Blood 94(6), 1848–1854 (1999).
  • Thorsélius M, Kröber A, Murray F et al. Strikingly homologous immunoglobulin gene rearrangements and poor outcome in VH3-21-using chronic lymphocytic leukemia patients independent of geographic origin and mutational status. Blood 107(7), 2889–2894 (2006).
  • Döhner H, Stilgenbauer S, Benner A et al. Genomic aberrations and survival in chronic lymphocytic leukemia. N. Engl. J. Med. 343(26), 1910–1916 (2000).
  • Tam CS, O’Brien S, Wierda W et al. Long-term results of the fludarabine, cyclophosphamide, and rituximab regimen as initial therapy of chronic lymphocytic leukemia. Blood 112(4), 975–980 (2008).
  • Gonzalez D, Martinez P, Wade R et al. Mutational status of the TP53 gene as a predictor of response and survival in patients with chronic lymphocytic leukemia: results from the LRF CLL4 trial. J. Clin. Oncol. 29(16), 2223–2229 (2011).
  • Letestu R, Rawstron A, Ghia P et al. Evaluation of ZAP-70 expression by flow cytometry in chronic lymphocytic leukemia: a multicentric international harmonization process. Cytometry B. Clin. Cytom. 70(4), 309–314 (2006).
  • Shenoy PJ, Malik N, Sinha R et al. Racial differences in the presentation and outcomes of chronic lymphocytic leukemia and variants in the United States. Clin. Lymphoma. Myeloma Leuk. 11(6), 498–506 (2011).
  • Bahlo J, Pflug N, Elter T et al. Proposal of a prognostic score for previously untreated patients with chronic lymphocytic leukemia based on an overall survival analysis of three German CLL Study Group Phase III trials. Presented at: American Society of Hematology 53rd Annual Meeting. San Diego, CA, USA, 10–13 December 2011. Blood 118(21), Abstract 2831 (2011).
  • Shanafelt TD, Jenkins G, Call TG et al. Validation of a new prognostic index for patients with chronic lymphocytic leukemia. Cancer 115(2), 363–372 (2009).
  • Wierda WG, O’Brien S, Wang X et al. Prognostic nomogram and index for overall survival in previously untreated patients with chronic lymphocytic leukemia. Blood 109(11), 4679–4685 (2007).
  • Ding W, Ferrajoli A. Evidence-based mini-review: the role of alkylating agents in the initial treatment of chronic lymphocytic leukemia patients with the 11q deletion. Hematology Am. Soc. Hematol. Educ. Program 2010, 90–92 (2010).
  • Zenz T, Eichhorst B, Busch R et al. TP53 mutation and survival in chronic lymphocytic leukemia. J. Clin. Oncol. 28(29), 4473–4479 (2010).
  • Pospisilova S, Gonzalez D, Malcikova J et al.; European Research Initiative on CLL (ERIC). ERIC recommendations on TP53 mutation analysis in chronic lymphocytic leukemia. Leukemia 26(7), 1458–1461 (2012).
  • Steele AJ, Prentice AG, Hoffbrand AV et al. p53-mediated apoptosis of CLL cells: evidence for a transcription-independent mechanism. Blood 112(9), 3827–3834 (2008).
  • Catovsky D, Else M, Richards S. Chlorambucil – still not bad: a reappraisal. Clin. Lymphoma. Myeloma Leuk. 11(Suppl. 1), S2–S6 (2011).
  • Eichhorst BF, Busch R, Stilgenbauer S et al.; German CLL Study Group (GCLLSG). First-line therapy with fludarabine compared with chlorambucil does not result in a major benefit for elderly patients with advanced chronic lymphocytic leukemia. Blood 114(16), 3382–3391 (2009).
  • Bracci L, Moschella F, Sestili P et al. Cyclophosphamide enhances the antitumor efficacy of adoptively transferred immune cells through the induction of cytokine expression, B-cell and T-cell homeostatic proliferation, and specific tumor infiltration. Clin. Cancer Res. 13(2 Pt 1), 644–653 (2007).
  • Schiavoni G, Sistigu A, Valentini M et al. Cyclophosphamide synergizes with type I interferons through systemic dendritic cell reactivation and induction of immunogenic tumor apoptosis. Cancer Res. 71(3), 768–778 (2011).
  • Robak T, Korycka A, Lech-Maranda E, Robak P. Current status of older and new purine nucleoside analogues in the treatment of lymphoproliferative diseases. Molecules 14(3), 1183–1226 (2009).
  • Johnston JB. Mechanism of action of pentostatin and cladribine in hairy cell leukemia. Leuk. Lymphoma 52(Suppl. 2), 43–45 (2011).
  • Genini D, Budihardjo I, Plunkett W et al. Nucleotide requirements for the in vitro activation of the apoptosis protein-activating factor-1-mediated caspase pathway. J. Biol. Chem. 275(1), 29–34 (2000).
  • Genini D, Adachi S, Chao Q et al. Deoxyadenosine analogs induce programmed cell death in chronic lymphocytic leukemia cells by damaging the DNA and by directly affecting the mitochondria. Blood 96(10), 3537–3543 (2000).
  • Di Gaetano N, Xiao Y, Erba E et al. Synergism between fludarabine and rituximab revealed in a follicular lymphoma cell line resistant to the cytotoxic activity of either drug alone. Br. J. Haematol. 114(4), 800–809 (2001).
  • Rai KR, Peterson BL, Appelbaum FR et al. Fludarabine compared with chlorambucil as primary therapy for chronic lymphocytic leukemia. N. Engl. J. Med. 343(24), 1750–1757 (2000).
  • Catovsky D, Richards S, Matutes E et al.; UK National Cancer Research Institute (NCRI) Haematological Oncology Clinical Studies Group; NCRI Chronic Lymphocytic Leukaemia Working Group. Assessment of fludarabine plus cyclophosphamide for patients with chronic lymphocytic leukaemia (the LRF CLL4 Trial): a randomised controlled trial. Lancet 370(9583), 230–239 (2007).
  • Johnson S, Smith AG, Löffler H et al. Multicentre prospective randomised trial of fludarabine versus cyclophosphamide, doxorubicin, and prednisone (CAP) for treatment of advanced-stage chronic lymphocytic leukaemia. The French Cooperative Group on CLL. Lancet 347(9013), 1432–1438 (1996).
  • Leporrier M, Chevret S, Cazin B et al.; French Cooperative Group on Chronic Lymphocytic Leukemia. Randomized comparison of fludarabine, CAP, and ChOP in 938 previously untreated stage B and C chronic lymphocytic leukemia patients. Blood 98(8), 2319–2325 (2001).
  • Robak T, Wierzbowska A, Robak E. Recent clinical trials of cladribine in hematological malignancies and autoimmune disorders. Rev. Recent Clin. Trials 1(1), 15–34 (2006).
  • Robak T, Blonski JZ, Kasznicki M et al. Cladribine with prednisone versus chlorambucil with prednisone as first-line therapy in chronic lymphocytic leukemia: report of a prospective, randomized, multicenter trial. Blood 96(8), 2723–2729 (2000).
  • CLL Trialists’ Collaborative Group. Systematic review of purine analog treatment for chronic lymphocytic leukemia: lessons for future trials. Haematologica 97(3), 428–436 (2012).
  • Dillman RO. Pentostatin (Nipent) in the treatment of chronic lymphocyte leukemia and hairy cell leukemia. Expert Rev. Anticancer Ther. 4(1), 27–36 (2004).
  • Strumberg D, Harstrick A, Doll K, Hoffmann B, Seeber S. Bendamustine hydrochloride activity against doxorubicin-resistant human breast carcinoma cell lines. Anticancer. Drugs 7(4), 415–421 (1996).
  • Leoni LM, Hartley JA. Mechanism of action: the unique pattern of bendamustine-induced cytotoxicity. Semin. Hematol. 48(Suppl. 1), S12–S23 (2011).
  • Knauf WU, Lissichkov T, Aldaoud A et al. Phase III randomized study of bendamustine compared with chlorambucil in previously untreated patients with chronic lymphocytic leukemia. J. Clin. Oncol. 27(26), 4378–4384 (2009).
  • Knauf WU, Lissitchkov T, Aldaoud A et al. Bendamustine compared with chlorambucil in previously untreated patients with chronic lymphocytic leukaemia: updated results of a randomized Phase III trial. Br. J. Haematol. 159(1), 67–77 (2012).
  • Niederle N, Balleisen L, Heit W. Bendamustine vs fludarabine as second-line treatment for patients with chronic lymphocytic leukemia – first interim results of a randomized study. Ann. Oncol. 19(Suppl. 4), iv194 (2008).
  • Clynes RA, Towers TL, Presta LG, Ravetch JV. Inhibitory Fc receptors modulate in vivo cytotoxicity against tumor targets. Nat. Med. 6(4), 443–446 (2000).
  • Reff ME, Carner K, Chambers KS et al. Depletion of B cells in vivo by a chimeric mouse human monoclonal antibody to CD20. Blood 83(2), 435–445 (1994).
  • Amoroso A, Hafsi S, Militello L et al. Understanding rituximab function and resistance: implications for tailored therapy. Front. Biosci. 16, 770–782 (2011).
  • Jazirehi AR, Huerta-Yepez S, Cheng G, Bonavida B. Rituximab (chimeric anti-CD20 monoclonal antibody) inhibits the constitutive nuclear factor-{κ}B signaling pathway in non-Hodgkin’s lymphoma B-cell lines: role in sensitization to chemotherapeutic drug-induced apoptosis. Cancer Res. 65(1), 264–276 (2005).
  • Bologna L, Gotti E, Manganini M et al. Mechanism of action of type II, glycoengineered, anti-CD20 monoclonal antibody GA101 in B-chronic lymphocytic leukemia whole blood assays in comparison with rituximab and alemtuzumab. J. Immunol. 186(6), 3762–3769 (2011).
  • Hainsworth JD, Litchy S, Barton JH et al.; Minnie Pearl Cancer Research Network. Single-agent rituximab as first-line and maintenance treatment for patients with chronic lymphocytic leukemia or small lymphocytic lymphoma: a Phase II trial of the Minnie Pearl Cancer Research Network. J. Clin. Oncol. 21(9), 1746–1751 (2003).
  • Thomas DA, O’Brien S, Giles FJ et al. Single agent rituximab in early stage chronic lymphocytic leukemia. Blood 98, 364a (2001).
  • Al-Kali A, Wierda W, Keating M, O’Brien S. Critical appraisal of the role of rituximab in the treatment of patients with previously untreated or treated chronic lymphocytic leukemia (CLL). J. Blood Med. 1, 115–122 (2010).
  • Byrd JC, Murphy T, Howard RS et al. Rituximab using a thrice weekly dosing schedule in B-cell chronic lymphocytic leukemia and small lymphocytic lymphoma demonstrates clinical activity and acceptable toxicity. J. Clin. Oncol. 19(8), 2153–2164 (2001).
  • O’Brien SM, Kantarjian H, Thomas DA et al. Rituximab dose-escalation trial in chronic lymphocytic leukemia. J. Clin. Oncol. 19(8), 2165–2170 (2001).
  • Prevodnik VK, Lavrencak J, Horvat M, Novakovic BJ. The predictive significance of CD20 expression in B-cell lymphomas. Diagn. Pathol. 6, 33 (2011).
  • Golay J, Lazzari M, Facchinetti V et al. CD20 levels determine the in vitro susceptibility to rituximab and complement of B-cell chronic lymphocytic leukemia: further regulation by CD55 and CD59. Blood 98(12), 3383–3389 (2001).
  • Beum PV, Kennedy AD, Williams ME, Lindorfer MA, Taylor RP. The shaving reaction: rituximab/CD20 complexes are removed from mantle cell lymphoma and chronic lymphocytic leukemia cells by THP-1 monocytes. J. Immunol. 176(4), 2600–2609 (2006).
  • Beum PV, Peek EM, Lindorfer MA et al. Loss of CD20 and bound CD20 antibody from opsonized B cells occurs more rapidly because of trogocytosis mediated by Fc receptor-expressing effector cells than direct internalization by the B cells. J. Immunol. 187(6), 3438–3447 (2011).
  • Kay NE, Zarling JM. Impaired natural killer activity in patients with chronic lymphocytic leukemia is associated with a deficiency of azurophilic cytoplasmic granules in putative NK cells. Blood 63(2), 305–309 (1984).
  • Flieger D, Emmerich B, Meyer N, Riethmüller G, Ziegler-Heitbrock HW. Deficient production of tumor necrosis factor by peripheral-blood monocytes in chronic lymphocytic leukemia. Int. J. Cancer 45(2), 280–286 (1990).
  • Foa R, Fierro MT, Lusso P et al. Reduced natural killer T-cells in B-cell chronic lymphocytic leukaemia identified by three monoclonal antibodies: Leu-11, A10, AB8.28. Br. J. Haematol. 62(1), 151–154 (1986).
  • Giannopoulos K, Schmitt M, Kowal M et al. Characterization of regulatory T cells in patients with B-cell chronic lymphocytic leukemia. Oncol. Rep. 20(3), 677–682 (2008).
  • Beyer M, Kochanek M, Darabi K et al. Reduced frequencies and suppressive function of CD4+CD25hi regulatory T cells in patients with chronic lymphocytic leukemia after therapy with fludarabine. Blood 106(6), 2018–2025 (2005).
  • Manshouri T, Do KA, Wang X et al. Circulating CD20 is detectable in the plasma of patients with chronic lymphocytic leukemia and is of prognostic significance. Blood 101(7), 2507–2513 (2003).
  • Byrd JC, Smith L, Hackbarth ML et al. Interphase cytogenetic abnormalities in chronic lymphocytic leukemia may predict response to rituximab. Cancer Res. 63(1), 36–38 (2003).
  • Bannerji R, Kitada S, Flinn IW et al. Apoptotic-regulatory and complement-protecting protein expression in chronic lymphocytic leukemia: relationship to in vivo rituximab resistance. J. Clin. Oncol. 21(8), 1466–1471 (2003).
  • Mone AP, Cheney C, Banks AL et al. Alemtuzumab induces caspase-independent cell death in human chronic lymphocytic leukemia cells through a lipid raft-dependent mechanism. Leukemia 20(2), 272–279 (2006).
  • Golay J, Manganini M, Rambaldi A, Introna M. Effect of alemtuzumab on neoplastic B cells. Haematologica 89(12), 1476–1483 (2004).
  • Nguyen TH, Havari E, McLaren R et al. Alemtuzumab induction of intracellular signaling and apoptosis in malignant B lymphocytes. Leuk. Lymphoma 53(4), 699–709 (2012).
  • Keating MJ, Flinn I, Jain V et al. Therapeutic role of alemtuzumab (Campath-1H) in patients who have failed fludarabine: results of a large international study. Blood 99(10), 3554–3561 (2002).
  • Hillmen P, Skotnicki AB, Robak T et al. Alemtuzumab compared with chlorambucil as first-line therapy for chronic lymphocytic leukemia. J. Clin. Oncol. 25(35), 5616–5623 (2007).
  • Cortelezzi A, Pasquini MC, Gardellini A et al. Low-dose subcutaneous alemtuzumab in refractory chronic lymphocytic leukaemia (CLL): results of a prospective, single-arm multicentre study. Leukemia 23(11), 2027–2033 (2009).
  • Stilgenbauer S, Zenz T, Winkler D et al.; German Chronic Lymphocytic Leukemia Study Group. Subcutaneous alemtuzumab in fludarabine-refractory chronic lymphocytic leukemia: clinical results and prognostic marker analyses from the CLL2H study of the German Chronic Lymphocytic Leukemia Study Group. J. Clin. Oncol. 27(24), 3994–4001 (2009).
  • Lozanski G, Heerema NA, Flinn IW et al. Alemtuzumab is an effective therapy for chronic lymphocytic leukemia with p53 mutations and deletions. Blood 103(9), 3278–3281 (2004).
  • Stilgenbauer S, Döhner H. Campath-1H-induced complete remission of chronic lymphocytic leukemia despite p53 gene mutation and resistance to chemotherapy. N. Engl. J. Med. 347(6), 452–453 (2002).
  • Moreton P, Kennedy B, Lucas G et al. Eradication of minimal residual disease in B-cell chronic lymphocytic leukemia after alemtuzumab therapy is associated with prolonged survival. J. Clin. Oncol. 23(13), 2971–2979 (2005).
  • Skoetz N, Bauer K, Elter T et al. Alemtuzumab for patients with chronic lymphocytic leukaemia. Cochrane Database Syst. Rev. 2, CD008078 (2012).
  • Lenihan DJ, Alencar AJ, Yang D, Kurzrock R, Keating MJ, Duvic M. Cardiac toxicity of alemtuzumab in patients with mycosis fungoides/Sézary syndrome. Blood 104(3), 655–658 (2004).
  • Gritti G, Reda G, Maura F et al. Low dose alemtuzumab in patients with fludarabine-refractory chronic lymphocytic leukemia. Leuk. Lymphoma 53(3), 424–429 (2012).
  • Bezares RF, Stemelin G, Diaz A et al. Multicenter study of subcutaneous alemtuzumab administered at reduced dose in patients with fludarabine-relapsed/refractory chronic lymphocytic leukemia: final analysis. Leuk. Lymphoma 52(10), 1936–1941 (2011).
  • Teeling JL, French RR, Cragg MS et al. Characterization of new human CD20 monoclonal antibodies with potent cytolytic activity against non-Hodgkin lymphomas. Blood 104(6), 1793–1800 (2004).
  • Rafiq S, Butchar JP, Cheney C et al. Comparative assessment of clinically utilized CD20-directed antibodies in chronic lymphocytic leukemia cells reveals divergent NK cell, monocyte, and macrophage properties. J. Immunol. 190(6), 2702–2711 (2013).
  • Wierda WG, Padmanabhan S, Chan GW, Gupta IV, Lisby S, Osterborg A; Hx-CD20-406 Study Investigators. Ofatumumab is active in patients with fludarabine-refractory CLL irrespective of prior rituximab: results from the Phase 2 international study. Blood 118(19), 5126–5129 (2011).
  • Wierda WG, Kipps TJ, Mayer J et al. Final analysis from the international trial of single-agent ofatumumab in patients with fludarabine-refractory chronic lymphocytic leukemia. Presented at: American Society of Hematology 52nd Annual Meeting. Orlando, FL, USA, 4–7 December 2010. Blood 116(21), Abstract 921 (2010).
  • Flinn IW, Harwin WN, Macias-Perez IM et al. A Phase II trial of ofatumumab for older patients and patients who refuse fludarabine-based regimens with previously untreated chronic lymphocytic leukemia or small lymphocytic lymphoma. Presented at: American Society of Hematology 53rd Annual Meeting. San Diego, CA, USA, 10–13 December 2011. Blood 118(21), Abstract 3912 (2011).
  • Yamauchi T, Nowak BJ, Keating MJ, Plunkett W. DNA repair initiated in chronic lymphocytic leukemia lymphocytes by 4-hydroperoxycyclophosphamide is inhibited by fludarabine and clofarabine. Clin. Cancer Res. 7(11), 3580–3589 (2001).
  • Johnston JB, Verburg L, Shore T, Williams M, Israels LG, Begleiter A. Combination therapy with nucleoside analogs and alkylating agents. Leukemia 8(Suppl. 1), S140–S143 (1994).
  • Kano Y, Akutsu M, Tsunoda S et al. In vitro cytotoxic effects of fludarabine (2-F-ara-A) in combination with commonly used antileukemic agents by isobologram analysis. Leukemia 14(3), 379–388 (2000).
  • Bellosillo B, Villamor N, Colomer D, Pons G, Montserrat E, Gil J. In vitro evaluation of fludarabine in combination with cyclophosphamide and/or mitoxantrone in B-cell chronic lymphocytic leukemia. Blood 94(8), 2836–2843 (1999).
  • Koehl U, Li L, Nowak B et al. Fludarabine and cyclophosphamide: synergistic cytotoxicity associated with inhibition of interstrand cross-link removal. Proc. Am. Assoc. Cancer Res. 38, A10 (1997).
  • Chow KU, Nowak D, Boehrer S et al. Synergistic effects of chemotherapeutic drugs in lymphoma cells are associated with down-regulation of inhibitor of apoptosis proteins (IAPs), prostate-apoptosis-response-gene 4 (Par-4), death-associated protein (Daxx) and with enforced caspase activation. Biochem. Pharmacol. 66(5), 711–724 (2003).
  • Schwänen C, Hecker T, Hübinger G et al. In vitro evaluation of bendamustine induced apoptosis in B-chronic lymphocytic leukemia. Leukemia 16(10), 2096–2105 (2002).
  • Chow KU, Boehrer S, Geduldig K et al. In vitro induction of apoptosis of neoplastic cells in low-grade non-Hodgkin’s lymphomas using combinations of established cytotoxic drugs with bendamustine. Haematologica 86(5), 485–493 (2001).
  • Roué G, López-Guerra M, Milpied P et al. Bendamustine is effective in p53-deficient B-cell neoplasms and requires oxidative stress and caspase-independent signaling. Clin. Cancer Res. 14(21), 6907–6915 (2008).
  • Flinn IW, Neuberg DS, Grever MR et al. Phase III trial of fludarabine plus cyclophosphamide compared with fludarabine for patients with previously untreated chronic lymphocytic leukemia: US Intergroup Trial E2997. J. Clin. Oncol. 25(7), 793–798 (2007).
  • Eichhorst BF, Busch R, Hopfinger G et al.; German CLL Study Group. Fludarabine plus cyclophosphamide versus fludarabine alone in first-line therapy of younger patients with chronic lymphocytic leukemia. Blood 107(3), 885–891 (2006).
  • Stilgenbauer S, Eichhorst BF, Busch R et al. Biologic and clinical markers for outcome after fludarabine (F) or F plus cyclophosphamide (FC) – comprehensive analysis of the CLL4 trial of the GCLLSG. Presented at: American Society of Hematology 50th Annual Meeting. San Francisco, CA, USA, 6–9 December 2008. Blood 112(11), Abstract 2089 (2008).
  • Elias L, Stock-Novack D, Head DR et al. A Phase I trial of combination fludarabine monophosphate and chlorambucil in chronic lymphocytic leukemia: a Southwest Oncology Group study. Leukemia 7(3), 361–365 (1993).
  • Weiss M, Spiess T, Berman E, Kempin S. Concomitant administration of chlorambucil limits dose intensity of fludarabine in previously treated patients with chronic lymphocytic leukemia. Leukemia 8(8), 1290–1293 (1994).
  • Robak T, Blonski JZ, Gora-Tybor J et al.; Polish Leukemia Group (PALG CLL2). Cladribine alone and in combination with cyclophosphamide or cyclophosphamide plus mitoxantrone in the treatment of progressive chronic lymphocytic leukemia: report of a prospective, multicenter, randomized trial of the Polish Adult Leukemia Group (PALG CLL2). Blood 108(2), 473–479 (2006).
  • Robak T, Jamroziak K, Gora-Tybor J et al. Comparison of cladribine plus cyclophosphamide with fludarabine plus cyclophosphamide as first-line therapy for chronic lymphocytic leukemia: a Phase III randomized study by the Polish Adult Leukemia Group (PALG-CLL3 Study). J. Clin. Oncol. 28(11), 1863–1869 (2010).
  • Tefferi A, Levitt R, Li CY et al. Phase II study of 2-chlorodeoxyadenosine in combination with chlorambucil in previously untreated B-cell chronic lymphocytic leukemia. Am. J. Clin. Oncol. 22(5), 509–516 (1999).
  • Weiss MA, Maslak PG, Jurcic JG et al. Pentostatin and cyclophosphamide: an effective new regimen in previously treated patients with chronic lymphocytic leukemia. J. Clin. Oncol. 21(7), 1278–1284 (2003).
  • Oken MM, Lee S, Kay NE, Knospe W, Cassileth PA. Pentostatin, chlorambucil and prednisone therapy for B-chronic lymphocytic leukemia: a Phase I/II study by the Eastern Cooperative Oncology Group study E1488. Leuk. Lymphoma 45(1), 79–84 (2004).
  • Köppler H, Heymanns J, Pandorf A, Weide R. Bendamustine plus mitoxantrone – a new effective treatment for advanced chronic lymphocytic leukaemia: results of a Phase I/II study. Leuk. Lymphoma 45(5), 911–913 (2004).
  • Furlan A, Villanova F, Pietrogrande F, Celadin M, Sanzari M, Vianello F. Low-dose fludarabine increases rituximab cytotoxicity in B-CLL cells by triggering caspases activation in vitro. Leuk. Lymphoma 51(1), 107–113 (2010).
  • Chow KU, Sommerlad WD, Boehrer S et al. Anti-CD20 antibody (IDEC-C2B8, rituximab) enhances efficacy of cytotoxic drugs on neoplastic lymphocytes in vitro: role of cytokines, complement, and caspases. Haematologica 87(1), 33–43 (2002).
  • Bezombes C, Fournié JJ, Laurent G. Direct effect of rituximab in B-cell-derived lymphoid neoplasias: mechanism, regulation, and perspectives. Mol. Cancer Res. 9(11), 1435–1442 (2011).
  • Cassano C, Mactier S, Mulligan SP, Belov L, Huang P, Christopherson RI. Cladribine and fludarabine nucleoside change the levels of CD antigens on B-lymphoproliferative disorders. Int. J. Proteomics 2010, 964251 (2010).
  • Alas S, Bonavida B. Rituximab inactivates signal transducer and activation of transcription 3 (STAT3) activity in B-non-Hodgkin’s lymphoma through inhibition of the interleukin 10 autocrine/paracrine loop and results in down-regulation of Bcl-2 and sensitization to cytotoxic drugs. Cancer Res. 61(13), 5137–5144 (2001).
  • Jazirehi AR, Vega MI, Chatterjee D, Goodglick L, Bonavida B. Inhibition of the Raf-MEK1/2-ERK1/2 signaling pathway, Bcl-xL down-regulation, and chemosensitization of non-Hodgkin’s lymphoma B cells by rituximab. Cancer Res. 64(19), 7117–7126 (2004).
  • Jazirehi AR, Bonavida B. Cellular and molecular signal transduction pathways modulated by rituximab (rituxan, anti-CD20 mAb) in non-Hodgkin’s lymphoma: implications in chemosensitization and therapeutic intervention. Oncogene 24(13), 2121–2143 (2005).
  • Vega MI, Huerta-Yepez S, Jazirehi AR, Garban H, Bonavida B. Rituximab (chimeric anti-CD20) sensitizes B-NHL cell lines to Fas-induced apoptosis. Oncogene 24(55), 8114–8127 (2005).
  • Smolewski P, Szmigielska-Kaplon A, Cebula B et al. Proapoptotic activity of alemtuzumab alone and in combination with rituximab or purine nucleoside analogues in chronic lymphocytic leukemia cells. Leuk. Lymphoma 46(1), 87–100 (2005).
  • Barth M, Hernandez-Ilizaliturri FJ, Mavis C et al. Ofatumumab, a fully human monoclonal antibody targeting CD20, demonstrates activity against and potentiates the anti-tumor activity of chemotherapy agents in rituximab-sensitive cell lines (RSCL), rituximab-resistant cell lines (RRCL), lymphoma xenografts, and primary tumor cells derived from patients with B-cell non-Hodgkin lymphoma (NHL). Presented at: American Society of Hematology 52nd Annual Meeting. Orlando, FL, USA, 4–7 December 2010. Blood 116(21), Abstract 3917 (2010).
  • Keating MJ, O’Brien S, Albitar M et al. Early results of a chemoimmunotherapy regimen of fludarabine, cyclophosphamide, and rituximab as initial therapy for chronic lymphocytic leukemia. J. Clin. Oncol. 23(18), 4079–4088 (2005).
  • Badoux XC, Keating MJ, Wang X et al. Fludarabine, cyclophosphamide, and rituximab chemoimmunotherapy is highly effective treatment for relapsed patients with CLL. Blood 117(11), 3016–3024 (2011).
  • Lamanna N, Jurcic JG, Noy A et al. Sequential therapy with fludarabine, high-dose cyclophosphamide, and rituximab in previously untreated patients with chronic lymphocytic leukemia produces high-quality responses: molecular remissions predict for durable complete responses. J. Clin. Oncol. 27(4), 491–497 (2009).
  • Bosch F, Abrisqueta P, Villamor N et al. Rituximab, fludarabine, cyclophosphamide, and mitoxantrone: a new, highly active chemoimmunotherapy regimen for chronic lymphocytic leukemia. J. Clin. Oncol. 27(27), 4578–4584 (2009).
  • Faderl S, Wierda W, O’Brien S, Ferrajoli A, Lerner S, Keating MJ. Fludarabine, cyclophosphamide, mitoxantrone plus rituximab (FCM-R) in frontline CLL <70 years. Leuk. Res. 34(3), 284–288 (2010).
  • Schulz H, Klein SK, Rehwald U et al.; German CLL Study Group. Phase 2 study of a combined immunochemotherapy using rituximab and fludarabine in patients with chronic lymphocytic leukemia. Blood 100(9), 3115–3120 (2002).
  • Byrd JC, Peterson BL, Morrison VA et al. Randomized Phase 2 study of fludarabine with concurrent versus sequential treatment with rituximab in symptomatic, untreated patients with B-cell chronic lymphocytic leukemia: results from Cancer and Leukemia Group B 9712 (CALGB 9712). Blood 101(1), 6–14 (2003).
  • Byrd JC, Rai K, Peterson BL et al. Addition of rituximab to fludarabine may prolong progression-free survival and overall survival in patients with previously untreated chronic lymphocytic leukemia: an updated retrospective comparative analysis of CALGB 9712 and CALGB 9011. Blood 105(1), 49–53 (2005).
  • Hallek M, Fischer K, Fingerle-Rowson G et al.; International Group of Investigators; German Chronic Lymphocytic Leukaemia Study Group. Addition of rituximab to fludarabine and cyclophosphamide in patients with chronic lymphocytic leukaemia: a randomised, open-label, Phase 3 trial. Lancet 376(9747), 1164–1174 (2010).
  • Robak T, Dmoszynska A, Solal-Céligny P et al. Rituximab plus fludarabine and cyclophosphamide prolongs progression-free survival compared with fludarabine and cyclophosphamide alone in previously treated chronic lymphocytic leukemia. J. Clin. Oncol. 28(10), 1756–1765 (2010).
  • Kay NE, Wu W, Kabat B et al. Pentostatin and rituximab therapy for previously untreated patients with B-cell chronic lymphocytic leukemia. Cancer 116(9), 2180–2187 (2010).
  • Kay NE, Geyer SM, Call TG et al. Combination chemoimmunotherapy with pentostatin, cyclophosphamide, and rituximab shows significant clinical activity with low accompanying toxicity in previously untreated B chronic lymphocytic leukemia. Blood 109(2), 405–411 (2007).
  • Lamanna N, Kalaycio M, Maslak P et al. Pentostatin, cyclophosphamide, and rituximab is an active, well-tolerated regimen for patients with previously treated chronic lymphocytic leukemia. J. Clin. Oncol. 24(10), 1575–1581 (2006).
  • Shanafelt TD, Lin T, Geyer SM et al. Pentostatin, cyclophosphamide, and rituximab regimen in older patients with chronic lymphocytic leukemia. Cancer 109(11), 2291–2298 (2007).
  • Dillman RO, Schreeder MT, Hon JK, Connelly EF, DePriest C, Cutter K. Community-based Phase II trial of pentostatin, cyclophosphamide, and rituximab (PCR) biochemotherapy in chronic lymphocytic leukemia and small lymphocytic lymphoma. Cancer Biother. Radiopharm. 22(2), 185–193 (2007).
  • Reynolds C, Di Bella N, Lyons RM et al. A Phase III trial of fludarabine, cyclophosphamide, and rituximab vs. pentostatin, cyclophosphamide, and rituximab in B-cell chronic lymphocytic leukemia. Invest. New Drugs 30(3), 1232–1240 (2012).
  • Bertazzoni P, Rabascio C, Gigli F et al. Rituximab and subcutaneous cladribine in chronic lymphocytic leukemia for newly diagnosed and relapsed patients. Leuk. Lymphoma 51(8), 1485–1493 (2010).
  • Robak T, Smolewski P, Cebula B, Grzybowska-Izydorczyk O, Blonski JZ. Rituximab plus cladribine with or without cyclophosphamide in patients with relapsed or refractory chronic lymphocytic leukemia. Eur. J. Haematol. 79(2), 107–113 (2007).
  • Fischer K, Cramer P, Busch R et al. Bendamustine combined with rituximab in patients with relapsed and/or refractory chronic lymphocytic leukemia: a multicenter Phase II trial of the German Chronic Lymphocytic Leukemia Study Group. J. Clin. Oncol. 29(26), 3559–3566 (2011).
  • Fischer K, Cramer P, Busch R et al. Bendamustine in combination with rituximab for previously untreated patients with chronic lymphocytic leukemia: a multicenter Phase II trial of the German Chronic Lymphocytic Leukemia Study Group. J. Clin. Oncol. 30(26), 3209–3216 (2012).
  • Weide R, Pandorf A, Heymanns J, Köppler H. Bendamustine/mitoxantrone/rituximab (BMR): a very effective, well tolerated outpatient chemoimmunotherapy for relapsed and refractory CD20-positive indolent malignancies. Final results of a pilot study. Leuk. Lymphoma 45(12), 2445–2449 (2004).
  • Weide R, Feiten S, Friesenhahn V et al. Retherapy with bendamustine-containing regimens in patients with relapsed/refractory CLL and indolent lymphomas achieves high response rates. Presented at: American Society of Hematology 53rd Annual Meeting. San Diego, CA, USA, 10–13 December 2011. Blood 118(21), Abstract 1615 (2011).
  • Wierda WG, Balakrishnan K, Ferrajoli A et al. A Phase I/II trial of fludarabine, bendamustine, and rituximab (FBR) chemoimmunotherapy for previously treated patients with CLL. Presented at: American Society of Hematology 53rd Annual Meeting. San Diego, CA, USA, 10–13 December 2011. Blood 118(21), Abstract 3901 (2011).
  • Sharman J, Flowers CR, Weiss M et al. Patterns of care for patients with chronic lymphocytic leukemia (CLL): The Connect® CLL Disease Registry. Presented at: American Society of Hematology 53rd Annual Meeting. San Diego, CA, USA, 10–13 December 2011. Blood 118(21), Abstract 2864 (2011).
  • Elter T, Borchmann P, Schulz H et al. Fludarabine in combination with alemtuzumab is effective and feasible in patients with relapsed or refractory B-cell chronic lymphocytic leukemia: results of a Phase II trial. J. Clin. Oncol. 23(28), 7024–7031 (2005).
  • Elter T, Gercheva-Kyuchukova L, Pylylpenko H et al. Fludarabine plus alemtuzumab versus fludarabine alone in patients with previously treated chronic lymphocytic leukaemia: a randomised Phase 3 trial. Lancet Oncol. 12(13), 1204–1213 (2011).
  • Elter T, James R, Stilgenbauer S et al. Chemoimmuno-therapy with fludarabine, cyclophosphamide and alemtuzumab (FC-Cam) in patients with relapsed or genetic high-risk CLL: final analysis of the CLL2L trial of the German CLL Study Group. Presented at: American Society of Hematology 51st Annual Meeting. New Orleans, LA, USA, 5–8 December 2009. Blood 114(22), Abstract 209 (2009).
  • Montillo M, Tedeschi A, Petrizzi VB et al. An open-label, pilot study of fludarabine, cyclophosphamide, and alemtuzumab in relapsed/refractory patients with B-cell chronic lymphocytic leukemia. Blood 118(15), 4079–4085 (2011).
  • Geisler CH, van ‘t Veer MMB, van Putten W et al. Immunochemotherapy with low-dose subcutaneous alemtuzumab (A) plus oral fludarabine and cyclophosphamide (FC) is safe and induces more and deeper complete remissions in untreated patients with high-risk chronic lymphocytic leukemia (CLL) than chemotherapy with FC alone. An early analysis of the randomized Phase-III HOVON68 CLL trial. Presented at: American Society of Hematology 53rd Annual Meeting. San Diego, CA, USA, 10–13 December 2011. Blood 118(21), Abstract 290 (2011).
  • Lepretre S, Aurran T, Mahe B et al. Immunochemotherapy with fludarabine (F), cyclophosphamide (C), and rituximab (R) (FCR) versus fludarabine (F), cyclophosphamide (C) and MabCampath (Cam) (FCCam) in previously untreated patients (pts) with advanced B-chronic lymphocytic leukemia (B-CLL): experience on safety and efficacy within a randomised multicenter Phase III trial of the French Cooperative Group On CLL and WM (FCGCLL/MW) and the ‘Groupe Ouest-Est d’Etudes Des Leucemies Aigues Et Autres Maladies Du sang’ (GOELAMS): CLL2007FMP (for fit medically patients). Presented at: American Society of Hematology 51st Annual Meeting. New Orleans, LA, USA, 5–8 December 2009. Blood 114(22), Abstract 538 (2009).
  • Parikh SA, Keating MJ, O’Brien S et al. Frontline chemoimmunotherapy with fludarabine, cyclophosphamide, alemtuzumab, and rituximab for high-risk chronic lymphocytic leukemia. Blood 118(8), 2062–2068 (2011).
  • Badoux XC, Keating MJ, Wang X et al. Cyclophosphamide, fludarabine, alemtuzumab, and rituximab as salvage therapy for heavily pretreated patients with chronic lymphocytic leukemia. Blood 118(8), 2085–2093 (2011).
  • Zent CS, LaPlant BR, Link BK et al. Pentostatin, alemtuzumab, and low dose rituximab is effective therapy for relapsed/refractory chronic lymphocytic leukemia/small lymphocytic lymphoma. Presented at: American Society of Hematology 53rd Annual Meeting. San Diego, CA, USA, 10–13 December 2011. Blood 118(21), Abstract 1790 (2011).
  • Veliz M, Pinilla-Ibarz J. Role of ofatumumab in treatment of chronic lymphocytic leukemia. J. Blood Med. 2, 71–77 (2011).
  • Shanafelt TD, Lanasa MC, Zent CS et al. Ofatumumab based chemoimmunotherapy (CIT) for patients with previously untreated CLL. Presented at: American Society of Hematology 53rd Annual Meeting. San Diego, CA, USA, 10–13 December 2011. Blood 118(21), Abstract 3898 (2011).
  • Wierda WG, Kipps TJ, Dürig J et al.; 407 Study Investigators. Chemoimmunotherapy with O-FC in previously untreated patients with chronic lymphocytic leukemia. Blood 117(24), 6450–6458 (2011).
  • Ujjani CS, Gehan EA, Ramzi P, Broome C, Cheson B. Ofatumumab and bendamustine in previously treated CLL and SLL. Presented at: American Society of Hematology 53rd Annual Meeting. San Diego, CA, USA, 10–13 December 2011. Blood 118(21), Abstract 4615 (2011).
  • Flowers CR. Improving our use and understanding of antibodies in B-cell lymphomas. Oncology 24(2), 176–177 (2010).
  • Alduaij W, Ivanov A, Honeychurch J et al. Novel type II anti-CD20 monoclonal antibody (GA101) evokes homotypic adhesion and actin-dependent, lysosome-mediated cell death in B-cell malignancies. Blood 117(17), 4519–4529 (2011).
  • Mössner E, Brünker P, Moser S et al. Increasing the efficacy of CD20 antibody therapy through the engineering of a new type II anti-CD20 antibody with enhanced direct and immune effector cell-mediated B-cell cytotoxicity. Blood 115(22), 4393–4402 (2010).
  • Morschhauser F, Cartron G, Lamy T et al. Phase I study of RO5072759 (GA101) in relapsed/refractory chronic lymphocytic leukemia. Presented at: American Society of Hematology 51st Annual Meeting. New Orleans, LA, USA, 5–8 December 2009. Blood 114(22), Abstract 884 (2009).
  • Goede V, Fischer K, Busch R et al. Chemoimmunotherapy with GA101 plus chlorambucil in patients with chronic lymphocytic leukemia and comorbidity: results of the CLL11 (BO21004) safety run-in. Leukemia 27(5), 1172–1174 (2013).
  • Awan FT, Pagel JM, Andritsos LA et al. Phase I study of Tru-016, an anti-CD37 SMIP™ protein in naive and relapsed and/or refractory CLL patients. Presented at: American Society of Hematology 53rd Annual Meeting. San Diego, CA, USA, 10–13 December 2011. Blood 118(21), Abstract 1792 (2011).
  • Byrd JC, Kipps TJ, Flinn IW et al. Phase 1/2 study of lumiliximab combined with fludarabine, cyclophosphamide, and rituximab in patients with relapsed or refractory chronic lymphocytic leukemia. Blood 115(3), 489–495 (2010).
  • Byrd JC, O’Brien S, Flinn IW et al. Phase 1 study of lumiliximab with detailed pharmacokinetic and pharmacodynamic measurements in patients with relapsed or refractory chronic lymphocytic leukemia. Clin. Cancer Res. 13(15 Pt 1), 4448–4455 (2007).
  • Byrd JC, Castro J, O’Brien S et al. Comparison of results from a Phase 1/2 study of lumiliximab (anti-CD23) in combination with FCR for patients with relapsed CLL with published FCR results. Presented at: American Society of Hematology 48th Annual Meeting. Orlando, FL, USA, 9–12 December 2006. Blood 108(11), Abstract 32 (2006).
  • Mahadevan D, Lanasa MC, Whelden M et al. First-in-human Phase I dose escalation study of a humanized anti-CD200 antibody (samalizumab) in patients with advanced stage B-cell chronic lymphocytic leukemia (B-CLL) or multiple myeloma (MM). Presented at: American Society of Hematology 52nd Annual Meeting. Orlando, FL, USA, 4–7 December 2010. Blood 116(21), Abstract 2465 (2010).
  • Furman RR, Forero-Torres A, Shustov A, Drachman JG. A Phase I study of dacetuzumab (SGN-40, a humanized anti-CD40 monoclonal antibody) in patients with chronic lymphocytic leukemia. Leuk. Lymphoma 51(2), 228–235 (2010).
  • Hertlein E, Triantafillou G, Sass EJ et al. Milatuzumab immunoliposomes induce cell death in CLL by promoting accumulation of CD74 on the surface of B cells. Blood 116(14), 2554–2558 (2010).
  • Byrd JC, Furman RR, Coutre SE et al. Targeting BTK with ibrutinib in relapsed chronic lymphocytic leukemia. N. Engl. J. Med. 369(1), 32–42 (2013).
  • Ponader S, Buggy J, O’Brien S, Wierda WG, Keating M, Burger JA. Bruton’s tyrosine kinase inhibitor PCI-32765 abrogates BCR- and nurselike cell-derived activation of CLL cells in vitro and in vivo. Presented at: American Society of Hematology 52nd Annual Meeting. Orlando, FL, USA, 4–7 December 2010. Blood 116(21), Abstract 45 (2010).
  • Cheson BD, Byrd JC, Rai KR et al. Novel targeted agents and the need to refine clinical end points in chronic lymphocytic leukemia. J. Clin. Oncol. 30(23), 2820–2822 (2012).
  • O’Brien SM, Barrientos JC, Flinn IW et al. Combination of the Bruton’s tyrosine kinase (BTK) inhibitor PCI-32765 with bendamustine (B)/rituximab (R) (BR) in patients (pts) with relapsed/refractory (R/R) chronic lymphocytic leukemia (CLL): interim results of a Phase Ib/II study. Presented at: American Society of Clinical Oncology Annual Meeting. Chicago, IL, USA, 1–5 June 2012. J. Clin. Oncol. 30(Suppl.), Abstract 6515 (2012).
  • Herman SE, Gordon AL, Wagner AJ et al. Phosphatidylinositol 3-kinase-d inhibitor CAL-101 shows promising preclinical activity in chronic lymphocytic leukemia by antagonizing intrinsic and extrinsic cellular survival signals. Blood 116(12), 2078–2088 (2010).
  • Furman RR, Byrd JC, Brown JR et al. CAL-101, an isoform-selective inhibitor of phosphatidylinositol 3-kinase P110ð, demonstrates clinical activity and pharmacodynamic effects in patients with relapsed or refractory chronic lymphocytic leukemia. Presented at: American Society of Hematology 52nd Annual Meeting. Orlando, FL, USA, 4–7 December 2010. Blood 116(21), Abstract 55 (2010).
  • Hoellenriegel J, Meadows SA, Sivina M et al. The phosphoinositide 3´-kinase δ inhibitor, CAL-101, inhibits B-cell receptor signaling and chemokine networks in chronic lymphocytic leukemia. Blood 118(13), 3603–3612 (2011).
  • Sharman J, de Vos S, Leonard JP et al. A Phase 1 study of the selective phosphatidylinositol 3-kinase-δ (PI3Kd) inhibitor, CAL-101 (GS-1101), in combination with rituximab and/or bendamustine in patients with relapsed or refractory chronic lymphocytic leukemia (CLL). Presented at: American Society of Hematology 53rd Annual Meeting. San Diego, CA, USA, 10–13 December 2011. Blood 118(21), Abstract 1787 (2011).
  • Tse C, Shoemaker AR, Adickes J et al. ABT-263: a potent and orally bioavailable Bcl-2 family inhibitor. Cancer Res. 68(9), 3421–3428 (2008).
  • Hanada M, Delia D, Aiello A, Stadtmauer E, Reed JC. bcl-2 gene hypomethylation and high-level expression in B-cell chronic lymphocytic leukemia. Blood 82(6), 1820–1828 (1993).
  • Miyashita T, Reed JC. Bcl-2 oncoprotein blocks chemotherapy-induced apoptosis in a human leukemia cell line. Blood 81(1), 151–157 (1993).
  • Wilson WH, O’Connor OA, Czuczman MS et al. Navitoclax, a targeted high-affinity inhibitor of BCL-2, in lymphoid malignancies: a Phase 1 dose-escalation study of safety, pharmacokinetics, pharmacodynamics, and antitumour activity. Lancet Oncol. 11(12), 1149–1159 (2010).
  • Kipps TJ, Swinnen LJ, Wierda WG et al. Navitoclax (ABT-263) plus fludarabine/cyclophosphamide/rituximab (FCR) or bendamustine/rituximab (BR): a Phase 1 study in patients with relapsed/refractory chronic lymphocytic leukemia (CLL). Presented at: American Society of Hematology 53rd Annual Meeting. San Diego, CA, USA, 10–13 December 2011. Blood 118(21), Abstract 3904 (2011).
  • Kahl B, Roberts AW, Seymour JF et al. Navitoclax (ABT-263) plus rituximab: interim results of a Phase 1 study in patients with CD20-positive lymphoid malignancies. Presented at: American Society of Hematology 52nd Annual Meeting. Orlando, FL, USA, 4–7 December 2010. Blood 116(21), Abstract 3943 (2010).
  • Friedberg JW, Sharman J, Sweetenham J et al. Inhibition of syk with fostamatinib disodium has significant clinical activity in non-Hodgkin lymphoma and chronic lymphocytic leukemia. Blood 115(13), 2578–2585 (2010).
  • Foon KA, Boyiadzis M, Land SR et al. Chemoimmunotherapy with low-dose fludarabine and cyclophosphamide and high dose rituximab in previously untreated patients with chronic lymphocytic leukemia. J. Clin. Oncol. 27(4), 498–503 (2009).
  • Woyach JA, Ruppert AS, Rai K et al. Impact of age on outcomes after initial therapy with chemotherapy and different chemoimmunotherapy regimens in patients with chronic lymphocytic leukemia: results of sequential cancer and leukemia group B studies. J. Clin. Oncol. 31(4), 440–447 (2013).
  • Badoux XC, Keating MJ, Wen S et al. Lenalidomide as initial therapy of elderly patients with chronic lymphocytic leukemia. Blood 118(13), 3489–3498 (2011).
  • Tsimberidou A-M, Keating MJ. Chronic lymphocytic leukemia/small lymphocytic leukemia. In: 60 years of survival outcomes at the University of Texas MD Anderson Cancer Center. Rodriguez MA, Walters RS, Burke TW (Eds). Springer, NY, USA, 211–224 (2013).
  • Willmore E, Elliott SL, Mainou-Fowler T et al. DNA-dependent protein kinase is a therapeutic target and an indicator of poor prognosis in B-cell chronic lymphocytic leukemia. Clin. Cancer Res. 14(12), 3984–3992 (2008).
  • Zolnierczyk JD, Komina O, Blonski JZ et al. Can ex vivo evaluation (testing) predict the sensitivity of CLL cells to therapy with purine analogs in conjunction with an alkylating agent? A comparison of in vivo and ex vivo responses to treatment. Med. Oncol. 29(3), 2111–2126 (2012).
  • Fiorcari S, Brown WS, McIntyre BW et al. The PI3 kinase (δ) inhibitor, CAL-101 (GS-1101), inhibits chronic lymphocytic leukemia (CLL) cell survival in endothelial and marrow stromal cell co-cultures. Presented at: American Society of Hematology 53rd Annual Meeting. San Diego, CA, USA, 10–13 December 2011. Blood 118(21), Abstract 1769 (2011).
  • Panayiotidis P, Jones D, Ganeshaguru K, Foroni L, Hoffbrand AV. Human bone marrow stromal cells prevent apoptosis and support the survival of chronic lymphocytic leukaemia cells in vitro. Br. J. Haematol. 92(1), 97–103 (1996).
  • Kurtova AV, Balakrishnan K, Chen R et al. Diverse marrow stromal cells protect CLL cells from spontaneous and drug-induced apoptosis: development of a reliable and reproducible system to assess stromal cell adhesion-mediated drug resistance. Blood 114(20), 4441–4450 (2009).
  • Reslan L, Dalle S, Tournebize AE, Herveau S, Cros E, Dumontet C. Comparison of cytotoxic mechanisms of anti-CD20 antibodies GA101 and rituximab against fresh chronic lymphocytic leukemia cells. Presented at: American Society of Hematology 52nd Annual Meeting. Orlando, FL, USA, 4–7 December 2010. Blood 116(21), Abstract 2467 (2010).
  • Jak M, van Bochove GG, Reits EA et al. CD40 stimulation sensitizes CLL cells to lysosomal cell death induction by type II anti-CD20 mAb GA101. Blood 118(19), 5178–5188 (2011).
  • Zhao X, Lapalombella R, Joshi T et al. Targeting CD37-positive lymphoid malignancies with a novel engineered small modular immunopharmaceutical. Blood 110(7), 2569–2577 (2007).
  • Robak T, Robak P, Smolewski P. TRU-016, a humanized anti-CD37 IgG fusion protein for the potential treatment of B-cell malignancies. Curr. Opin. Investig. Drugs 10(12), 1383–1390 (2009).
  • Smolewski P, Pawel R, Cebula-Obrzut B et al. Pro-apoptotic effect of an anti-CD37 Scfv-Fc fusion protein, in combination with the anti-CD20 antibody, ofatumumab, on tumor cells from B-cell malignancies. Presented at: American Society of Hematology 53rd Annual Meeting. San Diego, CA, USA, 10–13 December 2011. Blood 118(21), Abstract 1662 (2011).
  • Furman RR, Andritsos L, Flinn IW et al. Phase 1 dose escalation study of TRU-016, an anti-CD37 SMIPTM protein in relapsed and refractory CLL. Presented at: American Society of Hematology 52nd Annual Meeting. Orlando, FL, USA, 4–7 December 2010. Blood 116(21), Abstract 56 (2010).
  • Pathan NI, Chu P, Hariharan K, Cheney C, Molina A, Byrd J. Mediation of apoptosis by and antitumor activity of lumiliximab in chronic lymphocytic leukemia cells and CD23+ lymphoma cell lines. Blood 111(3), 1594–1602 (2008).
  • Shehata M, Schnabl S, Ponath E et al. Lumiliximab triggers apoptosis mechanisms in CLL cells through the inhibition of PI3-K/Akt pathway. Presented at: American Society of Hematology 51st Annual Meeting. New Orleans, LA, USA, 5–8 December 2009. Blood 114(22), Abstract 2371 (2009).
  • Maclaren A, Trauernicht A, Nguyen L, McLachlan K. Lumiliximab, an apoptosis sensitizer to multiple CLL therapeutic agents. Presented at: American Society of Hematology 50th Annual Meeting. San Francisco, CA, USA, 6–9 December 2008. Blood 112(11), Abstract 4209 (2008).
  • Khubchandani S, Czuczman MS, Hernandez-Ilizaliturri FJ. Dacetuzumab, a humanized mAb against CD40 for the treatment of hematological malignancies. Curr. Opin. Investig. Drugs 10(6), 579–587 (2009).
  • Lewis TS, McCormick RS, Emmerton K et al. Distinct apoptotic signaling characteristics of the anti-CD40 monoclonal antibody dacetuzumab and rituximab produce enhanced antitumor activity in non-Hodgkin lymphoma. Clin. Cancer Res. 17(14), 4672–4681 (2011).
  • Lewis TS, McCormick RS, Stone IJ et al. Proapoptotic signaling activity of the anti-CD40 monoclonal antibody dacetuzumab circumvents multiple oncogenic transformation events and chemosensitizes NHL cells. Leukemia 25(6), 1007–1016 (2011).
  • Samaniego F, Wise JF, Fayad L et al. Anti-CD74 antibody hLL1 is associated with lymphoma and chronic lymphocytic leukemia cell effects in vivo. Presented at: American Society of Hematology 53rd Annual Meeting. San Diego, CA, USA, 10–13 December 2011. Blood 118(21), Abstract 1796 (2011).
  • Stein R, Qu Z, Cardillo TM et al. Antiproliferative activity of a humanized anti-CD74 monoclonal antibody, hLL1, on B-cell malignancies. Blood 104(12), 3705–3711 (2004).
  • Herman SE, Gordon AL, Hertlein E et al. Bruton tyrosine kinase represents a promising therapeutic target for treatment of chronic lymphocytic leukemia and is effectively targeted by PCI-32765. Blood 117(23), 6287–6296 (2011).
  • de Rooij MF, Kuil A, Geest CR et al. The clinically active BTK inhibitor PCI-32765 targets B-cell receptor- and chemokine-controlled adhesion and migration in chronic lymphocytic leukemia. Blood 119(11), 2590–2594 (2012).
  • Ackler S, Mitten MJ, Foster K et al. The Bcl-2 inhibitor ABT-263 enhances the response of multiple chemotherapeutic regimens in hematologic tumors in vivo. Cancer Chemother. Pharmacol. 66(5), 869–880 (2010).
  • Roberts AW, Seymour JF, Brown JR et al. Substantial susceptibility of chronic lymphocytic leukemia to BCL2 inhibition: results of a Phase I study of navitoclax in patients with relapsed or refractory disease. J. Clin. Oncol. 30(5), 488–496 (2012).

Websites

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.